Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30272541 | 1.00 | GABRA1 (0.53) | GABRA1GABRB2GABRB1GABRA3TP53 | |
| SCHEMBL30279480 | 1.00 | GABRA1 (0.53) | GABRA1GABRB2GABRB1GABRA3TP53 | |
| SCHEMBL28906076 | 1.00 | GABRA1 (0.53) | GABRA1GABRB2GABRB1GABRA3TP53 | |
| SCHEMBL29196443 | 0.89 | PTPN22 (0.47) | TP53HSD17B10MEN1KMT2AL3MBTL1 | |
| SCHEMBL23924056 | 0.89 | PTPN22 (0.47) | TP53HSD17B10MEN1KMT2AL3MBTL1 | |
| SCHEMBL23947945 | 0.83 | GABRA1 (0.61) | GABRA1GABRB2GABRB1GABRA3TP53 | |
| SCHEMBL28906090 | 0.83 | GABRA1 (0.61) | GABRA1GABRB2GABRB1GABRA3TP53 | |
| SCHEMBL30272542 | 0.83 | GABRA1 (0.61) | GABRA1GABRB2GABRB1GABRA3TP53 | |
| SCHEMBL23951220 | 0.81 | PTPN22 (0.59) | GABRA1GABRB2GABRB1GABRA3TP53 | |
| SCHEMBL23947942 | 0.81 | PTPN22 (0.59) | GABRA1GABRB2GABRB1GABRA3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290333-A | Novel inhibitors of gonorrhoeae-specific tyrosine phosphatase (LYP) | 普渡研究基金会 | 2024-07-05 | — | — | CN | disclosed |
| CN-115461056-B | Inhibitors of Lebaba-specific tyrosine phosphatase (LYP) | 普渡研究基金会 | 2024-04-16 | — | — | CN | disclosed |
| CN-115461056-A | Novel lymphoid specific tyrosine phosphatase (LYP) inhibitors | 普渡研究基金会 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021211191-A1 | NOVEL LYMPHOID-SPECIFIC TYROSINE PHOSPHATASE (LYP) INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20210323926-A1 | Novel Lymphoid-Specific Tyrosine Phosphatase (LYP) Inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323926-A1 | Novel Lymphoid-Specific Tyrosine Phosphatase (LYP) Inhibitors | PTPN22, PTPN1, PTPRCAP | GABRA1 3349/4885GABRB2 3780/4885GABRB1 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.